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Background: Gram-negative bacteria such as Escherichia coli or Klebsiella spp. frequently cause bloodstream infections.
There has been a worldwide increase in resistance in these species to antibiotics such as third generation cephalosporins,
largely driven by the acquisition of extended-spectrum beta-lactamase or plasmid-mediated AmpC enzymes.
Carbapenems have been considered the most effective therapy for serious infections caused by such resistant
bacteria; however, increased use creates selection pressure for carbapenem resistance, an emerging threat arising
predominantly from the dissemination of genes encoding carbapenemases. Recent retrospective data suggest that
beta-lactam/beta-lactamase inhibitor combinations, such as piperacillin-tazobactam, may be non-inferior to
carbapenems for the treatment of bloodstream infection caused by extended-spectrum beta-lactamase-producers,
if susceptible in vitro. This study aims to test this hypothesis in an effort to define carbapenem-sparing alternatives for
these infections.
Methods/Design: The study will use a multicentre randomised controlled open-label non-inferiority trial design
comparing two treatments, meropenem (standard arm) and piperacillin-tazobactam (carbapenem-sparing arm)
in adult patients with bacteraemia caused by E. coli or Klebsiella spp. demonstrating non-susceptibility to third
generation cephalosporins. Recruitment is planned to occur in sites across three countries (Australia, New Zealand
and Singapore). A total sample size of 454 patients will be required to achieve 80% power to determine non-inferiority
with a margin of 5%. Once randomised, definitive treatment will be for a minimum of 4 days, but up to 14 days with
total duration determined by treating clinicians. Data describing demographic information, antibiotic use, co-morbid
conditions, illness severity, source of infection and other risk factors will be collected. Vital signs, white cell count, use of
vasopressors and days to bacteraemia clearance will be recorded up to day 7. The primary outcome measure will be
mortality at 30 days, with secondary outcomes including days to clinical and microbiological resolution, microbiological
failure or relapse, isolation of a multi-resistant organism or Clostridium difficile infection.
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Trial registration: The MERINO trial is registered under the Australian New Zealand Clinical Trials Register (ANZCTR),
reference number: ACTRN12613000532707 (registered 13 May 2013) and the US National Institute of Health
ClinicalTrials.gov register, reference number: NCT02176122 (registered 24 June 2014).
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Bloodstream infections caused by Gram-negative bacteria
such as Escherichia coli or Klebsiella spp. are commonly
encountered in clinical practice and may be associated with
significant mortality [1]. These bacteria may also acquire
genes encoding beta-lactamase enzymes that hydrolyse
essential beta-lactam antibiotics, rendering such treatment
ineffective. Isolates expressing extended-spectrum beta-
lactamase (ESBL) or plasmid-mediated AmpC enzymes are
increasingly encountered across the world, in both
community- and hospital-onset infections [2]. ESBL- or
AmpC-producers are typically resistant to third generation
cephalosporins such as ceftriaxone, but susceptible to car-
bapenems [3]. These bacteria are usually multi-resistant, as
beta-lactamase genes are frequently co-located with other
resistance mechanisms, leaving few treatment options.
Bacteraemia caused by resistant Gram-negative bacteria
may carry mortality in excess of those caused by suscep-
tible strains [4]. Thus, defining optimal treatment regimens
in these serious infections is of clinical importance. How-
ever, when selecting antimicrobial therapy, clinicians must
consider both efficacy of the chosen agent and downstream
risk such as selective pressure for further antimicrobial
resistance.
In observational studies that have been performed to
evaluate antibiotic choices for ESBL-producing Entero-
bacteriaceae, no agent has been shown to significantly
surpass carbapenems [5-8]. However, widespread use of
carbapenems may cause selection pressure for carbapenem
resistance [9,10]. Carbapenem-resistant Gram-negative
bacteria present a great therapeutic challenge, with suscep-
tibility often limited to ‘last-line’ antibiotics such as colistin
or tigecycline. Some new beta-lactam antibiotics and beta-
lactamase inhibitors, which are active against ESBL-,
AmpC- and some carbapenemase-producing organisms,
are in advanced clinical development [11,12]. However,
these antibiotics are likely to be expensive, are not yet on
the market and may best be held in reserve for infections
without therapeutic alternatives.
The susceptibility of AmpC- and ESBL-producers to
piperacillin-tazobactam is less predictable than carbapen-
ems. By definition, ESBLs are inhibited by beta-lactamase
inhibitors such as clavulanate or tazobactam [3]. However,
E. coli or Klebsiella spp. may also produce multiple beta-
lactamase types, some of which are resistant to inhibitionby tazobactam and may not be evident by susceptibility
testing alone. There have also been concerns that inocu-
lum effects may overwhelm the activity of beta-lactamase
inhibition in infections with a large bacterial burden [13].
Additionally, in some cases outer membrane protein loss
may contribute to resistance to tazobactam [14]. By defin-
ition, AmpC enzymes are also not well inhibited by tazo-
bactam [15], and plasmid-mediated AmpC expression
has been increasingly recognised as a cause of resistance
to expanded spectrum cephalosporins in Enterobacteria-
ceae [15]. However, despite these concerns, approxi-
mately 50% or more of ceftriaxone non-susceptible E. coli
or Klebsiella spp. remain susceptible to piperacillin-
tazobactam [16]. Yet, until recently, lack of published
clinical experience with the use of beta-lactam/beta-
lactamase inhibitor (BLBLI) agents for the treatment of
ESBL-producers has limited their use. As a result, carba-
penems have been perceived as a superior option. In recent
years we have witnessed an alarming increase in the preva-
lence and global dissemination of carbapenem-resistant
Gram-negative bacteria, largely driven by the spread of
genes encoding carbapenemase enzymes, transmitted on
highly mobile plasmids [17]. Thus, defining carbapenem-
sparing treatment options for ESBL-producers has become
imperative to reduce the selection pressure for carbapenem
resistance [10].
No randomised controlled trials (RCTs) have yet been
performed comparing different treatment options for
third generation cephalosporin-resistant Enterobacteria-
ceae. The largest observational study with an analysis by
treatment outcome was published in 2012 by Rodriguez-
Bano et al. [18]. They performed a post hoc analysis of
six prospective cohorts of patients with bacteraemia due
to ESBL-producing E. coli. Two non-mutually exclusive
cohorts (empirical therapy and definitive therapy) were
constructed and analysed separately. In both cohorts,
carbapenems were not superior to BLBLI combinations,
such as piperacillin-tazobactam. Specifically, in the de-
finitive therapy cohort, mortality rates at 30 days were
not significantly different - 9.3% for those who received
a BLBLI and 16.7% for those who received a carbapenem
(P > 0.20) [18]. A subsequent meta-analysis of all pub-
lished studies examining treatment options for bacter-
aemia caused by ESBL-producers also concluded that
BLBLI agents were non-inferior to carbapenems for both
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(CI) 0.23 to 1.13) or empirical therapy (RR 0.91, 95% CI
0.66 to 1.25) with regard to all-cause mortality [6]. In con-
trast, mortality was lower with carbapenems when com-
pared to non-BLBLI antibiotics (for example, quinolones)
for both definitive (RR 0.65, 95% CI 0.47 to 0.91) and em-
pirical treatment (RR 0.50, 95% CI 0.33 to 0.77).
Both meropenem and piperacillin-tazobactam are anti-
biotics that have been widely used in clinical practice for
many years. They have proven efficacy in a wide range
of infectious syndromes, including severe sepsis, febrile
neutropenia, ventilator-associated pneumonia and intra-
abdominal sepsis. Both agents are licensed for the treat-
ment of serious infections and are available for routine
clinical use in generic formulations. A non-inferiority study
design was selected because it is not ethically possible
to conduct a placebo-controlled trial and piperacillin-
tazobactam is not expected to be superior to merope-
nem with regard to the primary end-point. Instead,
potential benefits relate to minimisation of ‘collateral
damage’ in the form of selection for carbapenem-resistant
Enterobacteriaceae.Methods/Design
The trial protocol was developed by the Gram-negative
Working Group of the Australasian Society for Infectious
Disease Clinical Research Network (ASID-CRN), in ac-
cordance with the CONSORT statement extension for
‘Non-inferiority and Equivalence Trials’ [19].Table 1 Proposed participating sites
Country - State Facility
Australia - Queensland Royal Brisbane and Women’s Hospital
St. Andrew’s War Memorial Hospital
Brisbane Private HospitalHypothesis
Our hypothesis is that piperacillin-tazobactam is non-
inferior to meropenem for the definitive treatment of
bloodstream infections due to third generation cephalo-
sporin non-susceptible E. coli or Klebsiella spp.Princess Alexandra Hospital
The Mater Hospital
Australia - New South Wales Westmead Hospital
Wollongong Hospital
Australia - Victoria The Alfred Hospital
Monash Medical Centre
The Austin Hospital
Peter MacCallum Cancer Centre
Dandenong Hospital
Barwon Health
Australia - Western Australia Royal Perth Hospital
New Zealand North Shore Hospital, Auckland
Middlemore Hospital, Auckland
Singapore National University Hospital, Singapore
Tan Tock Seng Hospital, SingaporeStudy design
The study design will be a multicentre randomised con-
trolled non-inferiority open-label phase III trial. Both
study drugs (meropenem and piperacillin-tazobactam)
will be administered intravenously with standard dosing
regimens. The study population will be all adult pa-
tients (18 years of age or older, or 21 years or older at
Singapore sites) admitted to participating hospitals. Inclu-
sion in the study will be determined by the presence of a
bloodstream infection with E. coli or Klebsiella spp., as
defined by at least one positive blood culture from a
peripheral blood draw, where the isolate is confirmed
to be third generation cephalosporin non-susceptible, but
susceptible to piperacillin-tazobactam and meropenem
by European Committee for Antimicrobial Susceptibility
Testing (EUCAST) standards [20].Setting
The trial will be conducted in several centres across
Australia, New Zealand and Singapore (see Table 1).
Intervention
Meropenem 1 gram will be administered every 8 hours
intravenously or piperacillin-tazobactam 4.5 grams admin-
istered every 6 hours intravenously. Each dose will be
given over 30 minutes. The study drug is to be adminis-
tered for a minimum of 4 days and can be given for as
long as 14 days. The total duration of therapy will be de-
termined by the treating clinician. Dose adjustment for
renal impairment will be made according to the criteria in
Table 2. Blinding will not be performed as the two antibi-
otics have different dosing regimens. Follow-up will be for
30 days post enrolment. Other antimicrobials active against
Gram-negative bacilli are excluded in the first 4 days
after enrolment, except that trimethoprim/sulfamethoxazole
may be continued as Pneumocystis prophylaxis.
Primary objectives
 To compare the 30-day mortality post bloodstream
infection in patients treated with piperacillin-
tazobactam or meropenem
Secondary objectives
 To compare the time to clinical and microbiologic
resolution of infection for each regimen, defined as:
Table 2 Dose adjustment for study antibiotics
Meropenem Piperacillin-tazobactam
Creatinine clearance > 50 mL/min No change No change
Creatinine clearance 26 to 50 mL/min 1 g every 12 hours 4.5 g every 8 hours
Creatinine clearance 10 to 25 mL/min 500 mg every 12 hours 4.5 g every 12 hours
Creatinine clearance < 10 mL/min 500 mg every 24 hours 4.5 g every 12 hours
Haemodialysis 500 mg every 24 hours and
500 mg after each dialysis
2.25 g every 8 hours and an additional
0.75 g after each dialysis
Peritoneal dialysis 500 mg every 24 hours 2.25 g every 8 hours
Continuous-renal replacement therapy 1 g every 12 hours 4.5 g every 8 hours
Harris et al. Trials  (2015) 16:24 Page 4 of 8number of days from randomisation to resolution of
fever (temperature > 38.0°C) and leucocytosis (white
blood cell count > 12 × 109/L) PLUS sterilisation of
blood cultures
 To compare the clinical and microbiologic success
of each regimen at day 4 of the intervention, defined
as survival PLUS resolution of fever and leucocytosis
PLUS sterilisation of blood cultures. All of these
criteria will be assessed on day 4, counted from the
day of randomisation (day 1) in order to determine a
rapid response from the trial drug
 To compare microbiologic resolution of infection,
defined as sterility of blood cultures collected on or
before day 4
 To compare the risk of relapse with each regimen,
defined as growth of the same organism as in the
original blood culture after the end of the period of
study drug administration but before day 30
 To compare the risk of superinfection with a
carbapenem or piperacillin-tazobactam- resistant
organism or Clostridium difficile, defined as growth
of a meropenem or piperacillin-tazobactam-resistant
organism from any clinical specimen collected from
day 4 of study drug administration to day 30 or a
positive C. difficile stool test (with the method of
testing used according to local laboratory protocol).
This endpoint is important since one of the purposes
of establishing an alternative to carbapenem therapy
is to reduce infections with resistant organisms or
C. difficile.
Randomisation
Patients will be randomly assigned to either meropenem
or piperacillin-tazobactam in a 1:1 ratio according to a
randomisation list prepared in advance for each recruit-
ing site and stratification. Random sequence will be
generated using random permuted blocks of unequal
length. The randomisation process will be managed by the
Queensland Clinical Trials & Biostatistics Centre (QCTBC)
of The University of Queensland, and generated using an
online data management system (REDCap). Patients will
be stratified into 4 groups according to infecting species(E. coli or Klebsiella spp.) and disease severity (according
to a Pitt bacteraemia score [21] ≤ 4 or > 4; and presumed
site of infection from the urinary tract or elsewhere) (see
Figure 1).
Safety monitoring plan
A Data Monitoring and Safety Board (DMSB) will be
established, comprising two independent infectious dis-
ease physicians with statistical support provided to them
by the QCTBC. An interim analysis - including both ef-
ficacy and safety endpoints - will be performed after the
first 50 subjects have completed the 30-day study period.
The trial statistician will provide details of safety out-
comes and any significant differences in primary out-
comes according to treatment arm to the DMSB. The
stopping rule would be a statistically significant differ-
ence in primary outcomes between the two therapies.
Data entry and storage
A clinical database using the REDCap trial data manage-
ment system has been developed with a web hosting fa-
cility. Paper case report forms (CRFs) (Additional file 1)
will be completed and uploaded to the online system to
collect all clinical and additional laboratory-related infor-
mation (see Table 3). To ensure accurate transcription of
the CRF, double-data entry will be performed by a sec-
ond independent researcher. Any discrepancies, missing
data or errors will be clarified by discussion with the site
principal investigator. To ensure validity, a proportion
of CRFs will be checked by the local site investigators
against clinical and laboratory records.
Determination of sample size
As no randomised clinical trial has yet been conducted
in this particular field, the sample size estimation has been
derived from the retrospective study of bloodstream infec-
tion caused by ESBL-producing E. coli performed by
Rodriguez-Bano et al. [7]. The overall 30-day mortality in
their study was 16.7% in those patients who received a car-
bapenem (our control group). We have conducted a series
of simulations with possible variations in the observed
rates between the two treatment groups. Considering a
Figure 1 Patient stratification at enrolment.
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the 16.7% actually observed), and a non-inferiority margin
of 5% difference in the 2 groups, we would need 280 pa-
tients in total to achieve 80% power with a 1-sided alpha
level of 0.025. This allows for 10% dropout. It is likely that
mortality rates in observational cohorts may be greater
than those in a trial with exclusion criteria. Therefore, if
the observed mortality rate in the control group was 14%
(3% lower than that seen in the observational cohort), thenTable 3 Data collection
Variables
Demographic data Age, gender, ethnicity, long-term residential care st
Trial characteristics Date of screening and enrolment, inclusion criteria
Co-morbidities and
risk factors
Charlson score, co-morbid conditions, date and typ
immune suppressive medication, radiotherapy, biolo
presence of intravascular devices or urinary cathete
Infection parameters Bacteraemia acquisition status (community, healthc
infection, ICU admission, Pitt bacteraemia score, Acu
Antibiotic data From 48 hours prior to blood culture collection and
Clinical observations Daily vital signs, (highest temperature, HR, RR; lowe
use of pressors; recorded days 1 to 7; patient weigh
Microbiological data Date and time of initial blood culture, full susceptib
blood cultures and species identification/resistance
any multidrug-resistant organism or C. difficile ident
Outcome data Survival at 7 and 30 days post randomisation
Date of death or discharge
Length of hospital stay
Days to clinical and microbiological resolution
Clinical and microbiological success at day 4
Microbiological resolution or relapse
Protocol violations and adverse events
Reasons for study withdrawal
Abbreviations: BP blood pressure, HR heart rate, RR respiratory rate.under the same assumptions, we would need 454 patients
in total to achieve 80% power [22].
Actual mortality is expected to be similar in our study
population. We have performed a retrospective analysis of
92 bacteraemia episodes caused by ceftriaxone-resistant
E. coli or Klebsiella in Singapore (one of the trial sites)
over a 12-month period until May 2013, examining pa-
tients that would fulfil the MERINO trial inclusion cri-
teria. Average mortality at 30 days was 17.4% in patientsatus, ward location
and consent details, date and time of randomization
e of any surgery within 14 days, use of cytotoxic chemotherapy,
gical agents (for example, monoclonal antibody therapy),
rs; use of ‘not for resuscitation’ order
are-associated or hospital-acquired infection), presumed source of
te Physiology and Chronic Health Evaluation (APACHE) II score (if in ICU)
up to 30 days; dose/route/frequency recorded
st systolic BP), lowest arterial pCO2 (if ventilated), white cell count,
t
ility profile, daily blood culture results days 1 to 3; any further positive
profile; other clinical sites growing E coli or Klebsiella,
ified up to 30 days
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all mortality for all treatment groups was lower at 8.7%,
including those receiving BLBLIs (8.3%) [23].
Statistical and analytical plans
The intention-to-treat (ITT) analysis approach, sup-
ported by the per-protocol approach, will be adopted to
make inference on the possible non-inferiority of the
treatment arm, compared to the control arm, in terms of
30-day mortality. The proportions of deaths (with 95%
CIs) in the 2 study arms will be calculated. Logistic re-
gression with ‘treatment group’ as the only covariate will
be employed to draw inference on the possible non-
inferiority of the intervention treatment compared to the
control treatment. The odds ratio (with 95% CIs) will be
calculated with the meropenem arm as the reference
group. Appropriate parametric or non-parametric statis-
tical techniques will be employed to analyse the data for
secondary aims of the study. The Mann–Whitney U-test
will be used to compare median number of days to clinical
and microbiological resolution. Logistic regression will be
used to compare odds ratios of achieving clinical and
microbiological success and microbiological resolution at
day 4, as well as the odds ratio for microbiological relapse
and superinfection with a resistant organism between each
treatment arm. All secondary analyses will be based on an
ITT population.
An analysis of primary and secondary endpoints as de-
scribed above will be undertaken in a subgroup of ‘high
risk’ patients defined by a likely source of infection other
than the urinary tract or a Pitt bacteraemia score of >4.
Basic statistics in the study report will include infor-
mation on missing values for all relevant study variables.
A summary of baseline patient characteristics with totals
and proportions (%) for categorical variables, and mini-
mum, maximum, inter-quartile ranges and standard de-
viations for continuous variables will be presented. For
continuous study variables, box plots and Kernel density
plots will also be provided.
Protocol violations
All protocol violations occurring after randomisation
will be listed in the Clinical Study Report, tabulated by
subject and recruitment site. The final assignment of
participants to the per-protocol analysis population will
be made at a blinded protocol violation review meeting
prior to database lock.
Consent
Potential study participants will be identified on the basis
of positive blood cultures by liaison between the investiga-
tors and the clinical microbiologists. All patients who ful-
fill the microbiological inclusion criteria will be screened
for eligibility using a standardised screening form (seeAdditional file 2). The investigators will only approach the
patient with the agreement of the treating team. As soon
as practically possible after this discussion, the study team
representative will approach the patient at the bedside to
obtain consent. Typically this will be around 48 to 72
hours after the onset of clinical sepsis and the initial collec-
tion of blood cultures. For patients with cognitive impair-
ment secondary to their illness (for example, intubation
and ventilation, delirium), consent will be obtained from a
legally appropriate representative (for example, spouse),
where local regulatory requirements allow recruitment of
cognitively-impaired persons to clinical trials.
Study preparation and logistics
The trial coordination centre comprises the project
management team (THB, PH and DLP) at the University
of Queensland Centre for Clinical Research in Brisbane.
Site initiation and training will be conducted by PH,
DLP and THB via web conferencing and/or site visits.
Study sites will be contacted regularly via teleconference
to discuss any issues and ensure consistent study prac-
tices across sites.
Laboratory studies
All blood culture isolates will be made available to the
central trial laboratory at the University of Queensland
Centre for Clinical Research. Susceptibility testing, in-
cluding minimum inhibitory concentrations for key anti-
microbials, will be repeated in the central laboratory and
interpreted according to EUCAST standards. Additional
susceptibility testing for agents not tested at the recruit-
ing site laboratories will also be performed. Phenotypic
confirmation of ESBL or AmpC production will be per-
formed using combination disc testing [24]. Beta-lactamase
genes will be identified and characterized. Isolates will also
be screened for carbapenemase genes and other key anti-
microbial resistance determinants. Strain typing will
be determined using methods such as semi-automated
repetitive sequence-based PCR (rep-PCR) (DiversiLab;
BioMérieux, Marcy l’Étoile, France) and multi-locus se-
quence typing (MLST). Isolates will also be available for
whole genome sequencing.
Ethics
The protocol has been given ethical approval by the
Royal Brisbane and Women’s Hospital (ref: HREC/12/
QRBW/440), the National Healthcare Group (NHG)
Domain Specific Review Board (DSRB) in Singapore
(NHG DSRB ref: 2013/00453) and the New Zealand
Health and Disability Ethics Committee (Ref: 14/NTB/52).
Discussion
The quality and extent of evidence to help define opti-
mal treatment for many significant bacterial infections is
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ment of resistant Gram-negative bacteraemia, despite
being a major issue in daily practice for clinicians across
many specialties. In addition to laboratory data and ex-
pert opinion, current practice is almost entirely based on
retrospective observational studies, usually conducted in
single centres with relatively small numbers of patients.
Such studies, though informative, are always prone to
bias, thus weakening the strength of conclusions drawn
for these analyses. To date, there have been no RCTs re-
ported specifically comparing different treatment options
for ceftriaxone-resistant Enterobacteriaceae.
There is local support for the conduct of this study.
This is highlighted by a recent online survey in which
122 infectious diseases physicians in Australia and New
Zealand were asked to rank the research studies of great-
est immediate clinical relevance - the proposed trial
comparing meropenem and piperacillin-tazobactam was
the highest ranked RCT in the field of antibiotic resist-
ance in Gram-negative bacilli [25].
Antibiotic resistance is of tremendous public health
importance and has been recently described as poten-
tially the greatest current threat to human health [26].
The MERINO trial has potential significance for two
reasons. Firstly, it addresses treatment of a common but
serious antibiotic resistance issue that is associated with
10 to 20% mortality [5,18]. Secondly, proving that a
carbapenem-sparing antibiotic regimen is non-inferior to
a carbapenem will help encourage use of alternatives to
carbapenems. Carbapenem resistance is the ‘end-game’
with respect to antibiotic resistance as it eliminates one
of our most important antibiotic options and leaves few
effective alternative treatments. Evidenced-based strat-
egies to support the clinical management of resistant in-
fections that consider both efficacy and the potential for
‘collateral damage’ of treatment options are therefore ur-
gently needed.
Trial status
A pilot study based on this protocol has commenced re-
cruitment in both Singapore and Australia in February
2014. The remaining study sites are scheduled to begin
enrolment later during 2014 once local regulatory re-
quirements have been completed. It is planned for the
pilot phase to be extended to a definitive trial in early
2015. It is aimed that recruitment for the definitive study
will be completed by late 2016. Data from the pilot
phase will be included in the definitive study analysis.Additional files
Additional file 1: MERINO Trial Clinical Record Form.
Additional file 2: MERINO Trials Initial Screening Form.Abbreviations
APACHE: Acute Physiology and Chronic Health Evaluation; ASID: Australasian
Society for Infectious Disease; BLBLI: beta-lactam/beta-lactamase inhibitor;
CRF: Clinical record form; CRN: Clinical Research Network; DMSB: Data
Monitoring and Safety Board; DSRB: Domain Specific Review Board;
ESBL: extended-spectrum beta-lactamase; EUCAST: European Committee for
Antimicrobial Susceptibility Testing; QCTBC: Queensland Clinical Trials and
Biostatistics Unit; ITT: intention-to-treat; MLST: multi-locus sequence typing;
NHG: National Healthcare Group; PCR: polymerase chain reaction;
QCTBC: Queensland Clinical Trials and Biostatistics Unit; RCTs: randomised
controlled trials; RR: relative risk.
Competing interests
SKP has acted as a consultant and speaker for Novartis and Amylin
Pharmaceuticals, LLC. He has received grants in support of investigator and
investigator initiated clinical studies from Merck, Novo Nordisk and Pfizer,
Bristol Myer Squib, Amylin Pharmaceuticals and Hospira. SKP also received an
infrastructure research grant from Therapeutic Innovations Australia. DLP has
participated in advisory boards and received honoraria from AstraZeneca,
Merck, Pfizer, Bayer, Cubist and Leo Pharmaceuticals. All other authors have
no competing interests to declare.
Authors’ contributions
PH wrote the initial and final drafts of the manuscript. The concept for the
study was proposed by AYP and DLP. The original protocol was developed
by the Gram-negative Working Group of the ASID-CRN (AYP, JI, PRI, SM, AS,
BAR, ESM, EA, THB and DLP) with additional input from JL and JAR. Statistical
support was provided by SKP and PB. All authors have reviewed the final
manuscript and approve its contents.
Authors’ information
PH is an infectious disease physician and microbiologist and is currently
undertaking a PhD with the Paterson group at UQCCR. AYP is an infectious
disease physician and NHMRC Career Development Fellow. ESM is an
infectious diseases physician and is the head of epidemiology at the
Victorian Infectious Diseases Service. SM is a clinical academic infectious
diseases and general medicine physician. AJS is an infectious diseases
physician. PRI is an infectious diseases physician and microbiologist. BAR is
an infectious disease physician. JL is a critical care specialist. JAR is a clinical
pharmacist and NHMRC Research Fellow. JI is a physician and microbiologist
and runs the NHMRC Centre for Research Excellence in Critical Infection in
Sydney. EA is an infectious disease physician. SKP is a clinical trialist and
biostatistician. PB is a statistician. THB is a registered nurse and is currently
the Clinical Research Manager for the Paterson group at UQCCR. DLP is an
infectious disease physician and microbiologist and chairs the ASID-CRN
steering committee.
Acknowledgments
Funding for the trial has been received from the Australasian Society for
Antimicrobials (ASA) and the International Society for Chemotherapy (ISC).
We would like to acknowledge Anna Sartor (UQCCR) and Simon Forsyth
(QCTBC) for assistance in setting up the REDCap database and all local site
investigators for their involvement.
On behalf of the Australasian Society for Infectious Diseases Clinical Research
Network (ASID-CRN).
Author details
1University of Queensland Centre for Clinical Research, Building 71/918 Royal
Brisbane & Women’s Hospital Campus, Herston, 4029 Brisbane, QLD,
Australia. 2Department of Infectious Diseases, The Alfred Hospital, Melbourne,
VIC, Australia. 3Westmead Millenium Institute for Medical Research,
Westmead Hospital, Sydney, NSW, Australia. 4Department of Microbiology
and Infectious Diseases, Royal Perth Hospital, Perth, WA, Australia. 5School of
Pathology and Laboratory Medicine, University of Western Australia, Crawley,
WA, Australia. 6Department of Infectious Diseases, School of Medicine,
University of Wollongong and The Wollongong Hospital, Wollongong, NSW,
Australia. 7Department of Infectious Diseases, Austin Health, Melbourne, VIC,
Australia. 8Monash Infectious Disease, Monash Health, Clayton, VIC, Australia.
9Victorian Infectious Diseases Unit, Royal Melbourne Hospital, Melbourne, VIC,
Australia. 10Burns Trauma and Critical Care Research Centre, The University of
Queensland, Brisbane, QLD, Australia. 11Department of Infectious Disease,
Harris et al. Trials  (2015) 16:24 Page 8 of 8Barwon Health, Deakin University, Geelong, VIC, Australia. 12Clinical Trials &
Biostatistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, QLD,
Australia. 13Queensland Clinical Trials and Biostatistics Centre, University of
Queensland, Brisbane, QLD, Australia.
Received: 21 September 2014 Accepted: 22 December 2014
References
1. Cohen J, Cristofaro P, Carlet J, Opal S. New method of classifying infections
in critically ill patients. Crit Care Med. 2004;32(7):1510–26.
2. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing
Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis.
2008;8(3):159–66.
3. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical
update. Clin Microbiol Rev. 2005;18(4):657–86.
4. de Kraker MEA, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al.
Burden of antimicrobial resistance in European hospitals: excess mortality
and length of hospital stay associated with bloodstream infections due to
Escherichia coli resistant to third-generation cephalosporins. J Antimicrob
Chemother. 2011;66(2):398–407.
5. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H,
et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications
of production of extended-spectrum beta-lactamases. Clin Infect Dis.
2004;39(1):31–7.
6. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus
alternative antibiotics for the treatment of bacteraemia due to
Enterobacteriaceae producing extended-spectrum beta-lactamases:
a systematic review and meta-analysis. J Antimicrob Chemother.
2012;67(12):2793–803.
7. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. beta-Lactam/
beta-lactam inhibitor combinations for the treatment of bacteremia due to
extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc
analysis of prospective cohorts. Clin Infect Dis. 2012;54(2):167–74.
8. Peralta G, Lamelo M, Alvarez-Garcia P, Velasco M, Delgado A, Horcajada JP,
et al. Impact of empirical treatment in extended-spectrum beta-lactamase-
producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric
cohort study. BMC Infect Dis. 2012;12:245.
9. McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH.
Correlations of antibiotic use and carbapenem resistance in
Enterobacteriaceae. Antimicrob Agents Chemother. 2013;57(10):5131–3.
10. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant
Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis.
2011;53(1):60–7.
11. Boucher HW, Talbot GH, Benjamin Jr DK, Bradley J, Guidos RJ, Jones RN,
et al. Infectious Diseases Society of A: 10 × ′20 progress-development of
new drugs active against gram-negative bacilli: an update from the Infectious
Diseases Society of America. Clin Infect Dis. 2013;56(12):1685–94.
12. Drawz SM, Papp-Wallace KM, Bonomo RA. New beta-lactamase inhibitors:
a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother.
2014;58(4):1835–46.
13. Tam VH, Ledesma KR, Chang KT, Wang TY, Quinn JP. Killing of Escherichia
coli by beta-lactams at different inocula. Diagn Microbiol Infect Dis.
2009;64(2):166–71.
14. Rice LB, Carias LL, Hujer AM, Bonafede M, Hutton R, Hoyen C, et al.
High-level expression of chromosomally encoded SHV-1 beta-lactamase
and an outer membrane protein change confer resistance to ceftazidime and
piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2000;44(2):362–7.
15. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22(1):161–82.
16. Chen YH, Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, et al.
Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative
bacilli isolated from patients with intra-abdominal infections in the
Asia-Pacific region according to currently established susceptibility
interpretive criteria. J Infect. 2011;62(4):280–91.
17. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL.
Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae:
an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682–707.
18. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. Extended-Spectrum
Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa/Grupo
de Estudio de Infeccion Hospitalaria G. beta-Lactam/beta-lactam inhibitorcombinations for the treatment of bacteremia due to extended-spectrum
beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective
cohorts. Clin Infect Dis. 2012;54(2):167–74.
19. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, Group C.
Reporting of noninferiority and equivalence randomized trials: extension of
the CONSORT 2010 statement. JAMA. 2012;308(24):2594–604.
20. Breakpoint tables for interpretation of MICs and zone diameters version 4.0.
Available from: http://www.eucast.org. Accessed 6th December 2014.
21. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H,
et al. International prospective study of Klebsiella pneumoniae bacteremia:
implications of extended-spectrum beta-lactamase production in nosocomial
Infections. Ann Intern Med. 2004;140(1):26–32.
22. Chow S-C, Hansheng W, Shao J. Sample size calculations in clinical research.
2nd ed. Boca Raton: Chapman Hall; 2007.
23. Harris PNA, Mo Y, Jureen R, Chew J, Ali J, Paterson DL, Tambyah PA.
Meropenem and piperacillin-tazobactam have comparable outcomes in
treatment of bloodstream infections caused by extended spectrum
beta-lactamase producing E.coli and Klebsiellae. Abstract number 486,
IDWeek. Philadelphia, PA: 8 to 12 October 2014. Available from:
https://idsa.confex.com/idsa/2014/webprogram/Paper46679.html.
Accessed 12th Jan 2015.
24. EUCAST guidelines for detection of resistance mechanisms and specific
resistances of clinical and/or epidemiological importance. Available from:
http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_
mechanisms/EUCAST_detection_of_resistance_mechanisms_v1.0_20131211.
pdf. Accessed 26th Jan 2015.
25. Paterson DL. Determining research priorities for clinician-initiated trials in
infectious diseases. Med J Aust. 2013;198(5):270–2.
26. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance.
N Engl J Med. 2013;368(4):299–302.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
